Life Sciences

Pharma executives wary of value-based deals: PwC

September 22, 2017

A rush of headlines may make it seem as if value-based contracting is taking over the pharma industry as health systems grapple with high drug costs. But a new survey from PwC finds the pricing model has yet to take off in any major way…

Impax CEO Bisaro reportedly putting his M&A moves on Amneal

September 22, 2017

When former Allergan chairman Paul Bisaro took over at Impax Labs, everyone wondered if his extensive M&A experience would eventually lead the generics maker to a deal. Wonder no more. Impax is reportedly in merger talks with generics competitor Amneal Pharmaceuticals. The two companies, which..

Eyeing drug sales, Amazon starts talks with PBMs: report

September 21, 2017

Rumors that Amazon is looking to parachute into the drug field are getting louder. Amazon is already in talks with pharmacy benefits managers, an analyst reports, and that poses a larger threat to the pharma industry than some might realize. The retail giant has stayed..

Roche unloads another plant in Recipharm deal; saves 200 jobs

September 21, 2017

Roche, which has been trying for two years to offload four small-molecule manufacturing plants around the world, will sell one in Spain to Recipharm in a deal that will save another 200 jobs. As part of the arrangement to take over the plant in Leganés,..

Brazil drugmaker Blau in talks with banks for IPO -sources

September 20, 2017

Blau Farmacêutica SA, a Brazilian maker of kidney and cancer medicines, is working with banks on an initial public offering aimed at raising money to accelerate an expansion drive across Latin America, three people familiar with the matter said. Blau has discussed underwriting roles with..

Ex-Glaxo CEO Witty joins Hatteras as venture partner

September 19, 2017

Sir Andrew Witty has joined Hatteras Venture Partners. The former GlaxoSmithKline CEO is taking up a venture partner position at the VC shop, setting him up to offer advice on the positioning of its portfolio companies. Witty stepped down as GSK CEO earlier this year..

Catalent doubles down on biologics with $950M deal for Cook Pharmica

September 19, 2017

Catalent signaled a year ago that it was looking for the right M&A target to bulk up like some of its competitors have. Now it says it has found one, having agreed to pay $950 million to buy Cook Pharmica and its extensive biologics manufacturing..

Teva finishes women’s health sale with deals worth $1.38B

September 18, 2017

Teva, which has been rumored to be looking to offload its women’s health unit since April, has finally gotten that done. After selling one piece of the biz for more than $1 billion a week ago, the beleaguered drugmaker today unveiled terms to sell the..

Gates invests in Immunocore to spur infectious disease R&D

September 18, 2017

The Bill & Melinda Gates Foundation is investing up to $40 million in Immunocore to spur research into the use of T cell receptor (TCR)-based therapeutics to treat tuberculosis and HIV. Immunocore is primarily known for its work in cancer. That is what prompted AstraZeneca,..

Fosun Pharma buys smaller stake in Gland Pharma for $1.1 billion

September 18, 2017

Shanghai Fosun Pharmaceutical Group is trimming the size of the stake it will buy in India’s Gland Pharma to 74 percent for $1.1 billion, in a bid to salvage the stalled deal that would be the biggest takeover by a Chinese firm in India. Fosun..